使用EORTC QLQ-TC26的丸癌幸存者的不良事件:日本的一项多机构,横截面研究
Takuro Goto1, Shinichi Yamashita1, Kenichi Kakimoto2
1Department of Urology, Tohoku University Graduate School of Medicine, Sendai, Japan.
概括
丸癌幸存者经历了长期的不良事件,特别是听力问题,经过三次或更多的化疗周期. 和麻木可能会改善,但听力问题仍然存在,需要更好的患者信息.
科学领域:
- 在瘤学瘤学.
- 幸存者护理 幸存者护理
- 生活质量研究 研究 生命质量研究
背景情况:
- 丸癌治疗可能导致长期的不良事件,影响幸存者的生活质量.
- 欧洲癌症研究和治疗组织的生命质量调查问卷-瘤26 (EORTC QLQ-TC26) 是评估这些问题的关键工具.
研究的目的:
- 评估丸癌幸存者的不良事件的发生率和特征.
- 评估化疗周期和paclitaxel使用对这些不良事件的影响.
主要方法:
- 一项来自日本八个机构的551名丸癌幸存者的调查.
- 收集的数据包括人口统计数据,治疗细节 (化疗周期,帕克利塔塞尔使用),随访持续时间和EORTC QLQ-TC26不良事件评分.
主要成果:
- 接受三次或以上化疗周期的幸存者报告了明显更差的不良事件得分.
- 化疗影响了外围神经病变 (刺痛/麻木,四肢感冒) 和听力问题的得分.
- 周围神经病变倾向于随着时间的推移而改善,而听力问题没有得到改善.
结论:
- 经过强化化疗后,丸癌幸存者经历了持续的不良事件,特别是听力损伤.
- 长期的不良事件,特别是听力问题,需要更好的患者教育和管理策略.
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...


